Market Research Logo

Obesity - Pipeline Review, H1 2018

Obesity - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H1 2018, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 18, 28, 1, 120, 32 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 53 and 10 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Obesity - Overview
Obesity - Therapeutics Development
Obesity - Therapeutics Assessment
Obesity - Companies Involved in Therapeutics Development
Obesity - Drug Profiles
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Obesity, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Obesity - Pipeline by Abeome Corp, H1 2018
Obesity - Pipeline by Adocia SAS, H1 2018
Obesity - Pipeline by Aegis Therapeutics LLC, H1 2018
Obesity - Pipeline by Amgen Inc, H1 2018
Obesity - Pipeline by Antag Therapeutics ApS, H1 2018
Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018
Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018
Obesity - Pipeline by AstraZeneca Plc, H1 2018
Obesity - Pipeline by Athersys Inc, H1 2018
Obesity - Pipeline by Auris Medical Holding AG, H1 2018
Obesity - Pipeline by Bial - Portela & Ca SA, H1 2018
Obesity - Pipeline by Biophytis SA, H1 2018
Obesity - Pipeline by BioRestorative Therapies Inc, H1 2018
Obesity - Pipeline by Biozeus, H1 2018
Obesity - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Obesity - Pipeline by Braasch Biotech LLC, H1 2018
Obesity - Pipeline by C3J Therapeutics Inc, H1 2018
Obesity - Pipeline by Callitas Therapeutics Inc, H1 2018
Obesity - Pipeline by Carmot Therapeutics Inc, H1 2018
Obesity - Pipeline by Celon Pharma SA, H1 2018
Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Obesity - Pipeline by CohBar Inc, H1 2018
Obesity - Pipeline by CoMentis Inc, H1 2018
Obesity - Pipeline by Corcept Therapeutics Inc, H1 2018
Obesity - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Obesity - Pipeline by DiscoveryBiomed Inc, H1 2018
Obesity - Pipeline by Eisai Co Ltd, H1 2018
Obesity - Pipeline by Eli Lilly and Co, H1 2018
Obesity - Pipeline by Eternygen GmbH, H1 2018
Obesity - Pipeline by Evotec AG, H1 2018
Obesity - Pipeline by FibroGen Inc, H1 2018
Obesity - Pipeline by Genmedica Therapeutics SL, H1 2018
Obesity - Pipeline by Gila Therapeutics Inc, H1 2018
Obesity - Pipeline by Gilead Sciences Inc, H1 2018
Obesity - Pipeline by GlaxoSmithKline Plc, H1 2018
Obesity - Pipeline by Glucox Biotech AB, H1 2018
Obesity - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018
Obesity - Pipeline by Immungenetics AG, H1 2018
Obesity - Pipeline by Intarcia Therapeutics Inc, H1 2018
Obesity - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Obesity - Pipeline by Johnson & Johnson, H1 2018
Obesity - Pipeline by Juno Therapeutics Inc, H1 2018
Obesity - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
Obesity - Pipeline by Lead Discovery Center GmbH, H1 2018
Obesity - Pipeline by Leading BioSciences Inc, H1 2018
Obesity - Pipeline by Magnus Life Ltd, H1 2018
Obesity - Pipeline by MedImmune LLC, H1 2018
Obesity - Pipeline by Merck & Co Inc, H1 2018
Obesity - Pipeline by Naia Ltd, H1 2018
List of Figures
Number of Products under Development for Obesity, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report